Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer

ClinicalTrials.gov ID: NCT00051688

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00051688. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.

Study identification

NCT ID: NCT00051688
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Chiron Corporation; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Colorectal Neoplasms

Interventions

tezacitabine Drug
oxaliplatin Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2003 (Type not available)
Primary completion: Not listed
Completion: Aug 2004 (Type not available)
Last update posted: Jul 11, 2006

2003 – 2004

United States locations

U.S. sites: 8
U.S. states: 6
U.S. cities: 8

Facility	City	State	ZIP	Site status
ACRC/Arizona Clinical Research Center	Tucson	Arizona	85712	—
USC/Norris Comprehensive Cancer Center	Los Angeles	California	90033	—
Comprehensive Cancer Centers of the Desert	Palm Springs	California	92262	—
Cancer Institute Medical Group	Santa Monica	California	90404	—
Georgetown University Medical Center, Lombardi Cancer Center	Washington D.C.	District of Columbia	20007	—
H. Lee Moffitt Cancer Center & Research Institute	Tampa	Florida	33612-9497	—
Northwestern University Feinberg School of Medicine	Chicago	Illinois	60611	—
Kansas City Oncology and Hematology Group	Kansas City	Missouri	64111	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00051688, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 11, 2006 · Synced Nov 12, 2026